These trials revealed major CV benefits with GLP-1R agonists and SGLT2 inhibitors, which has led to a paradigm shift in the management of T2DM in patients with CV comorbidities and a recognition of the cardiometabolic effects of contemporary glucocentric drugs. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.